• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 461654 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414694864 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414694864 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulate Shares of United Therapeutics, Up 1.6%

Published on Mon, 03/18/2013 - 12:29
By Mallory Stone

United Therapeutics (NASDAQ:UTHR), a company whose shares are moving quickly, is trading 1.6% higher to $62.01. The Dow is trading fractionally lower to 14,492 and the S&P is currently down 0.3% to 1,555.

In the past 52 weeks, United Therapeutics share prices have been bracketed by a low of $36.55 and a high of $70.74 and are now at $62.01, 70% above that low price. The 200-day and 50-day moving averages have moved 0.90% higher and 1.65% higher over the past week, respectively.

United Therapeutics (NASDAQ:UTHR) is currently priced 8.5% above its average consensus analyst price target of $56.73. The stock should discover initial support at its 50-day moving average (MA) of $55.84 and subsequent support at its 200-day MA of $53.10.

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Sellers Reduce Exposure to Shares of Die...

Shares of Diebold are trading today in above average volume, with the share price falli ...

Shares of Greenhill Are Moving Lower on ...

Shares of Greenhill are trading today in above average volume, with the share price fal ...

Volume Spike Detected in Shares of Hornb...

Shares of Hornbeck Offshore Services are trading today in above average volume, with th ...

Volume Spike Detected in Shares of Ameri...

Shares of American Railcar Industries are trading today in above average volume, with t ...

Equinix's Shares Changing Hands at Highe...

Shares of Equinix are trading today in above average volume, with the share price risin ...

Shares of Holly Energy Partners Receive ...

Holly Energy Partners (NYSE:HEP), a company whose shares are moving quickly, is trading ...

K12's Shares Changing Hands at Lower Pri...

K12's stock is down 12.2% to $13.30 on heavy trading volume. Approximately 584,000 sha ...

Stock Investors Sell Off Shares of Cree,...

Down 1.8% to $31.28, Cree (NASDAQ:CREE), is one of today's notable movers. The S&P is ...